Suppliers and packagers for generic pharmaceutical drug: ganciclovir

ganciclovir

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb	ZIRGAN	ganciclovir	GEL;OPHTHALMIC	022211	NDA	Bausch & Lomb Incorporated	24208-535-15	1 TUBE, WITH APPLICATOR in 1 CARTON (24208-535-15) / 1.5 g in 1 TUBE, WITH APPLICATOR	2010-04-30
Bausch And Lomb	ZIRGAN	ganciclovir	GEL;OPHTHALMIC	022211	NDA	Bausch & Lomb Incorporated	24208-535-35	1 TUBE, WITH APPLICATOR in 1 CARTON (24208-535-35) / 5 g in 1 TUBE, WITH APPLICATOR	2010-04-30

Ganciclovir API and Drug Product Suppliers: Who Manufactures It, What Inputs They Sell, and Where Supply Risks Concentrate

Last updated: May 27, 2026

Ganciclovir supply splits into (1) API manufacturers selling bulk drug substance and (2) finished-goods makers producing oral capsules, oral solution, and injectable drug product for markets that include the US and EU. The supplier set varies by dosage form and by whether buyers contract for generic/contract manufacturing or branded procurement.

Who supplies ganciclovir API (bulk drug substance) and how is the supply chain structured?

Ganciclovir API procurement is typically sourced through a short list of global bulk-API suppliers that also produce related guanine nucleoside analogs (antivirals) and nucleoside intermediates. Contract terms usually cover API CoA, DMF/ASMF referencing where applicable, and release testing for identity, assay, and impurities.

Typical sourcing pattern

• API purchased as ganciclovir (bulk drug substance).
• Drug product produced either by:
  • original manufacturer of record for that NDA/ANDA, or
  • contract development and manufacturing organizations (CDMOs) making multiple antiviral generics across several strengths.

Common supply-chain chokepoints

• Nucleoside analog intermediates (guanine ring construction and glycosylation chemistry).
• High-spec impurity control on nucleoside analogs.
• Sterile fill-finish capacity for IV ganciclovir batches when buyers source injectable strengths.

Which regions dominate ganciclovir API supply?

Most commercial ganciclovir API supply concentrates in:

• India (bulk API scale and generic antiviral production)
• China (bulk antiviral nucleoside analog manufacturing)
• Europe and Japan (more often finished dose and some API niches, depending on company)

What do buyers contract for besides API?

• DMF/ASMF linkage to support regulatory filings (where used).
• Particle size and polymorph controls (where specified by buyers).
• Impurity specifications aligned to pharmacopeia and NDA/ANDA acceptance.
• Packaging format and stability constraints for nucleoside analogs.

Which companies are the primary finished-goods manufacturers for ganciclovir capsules, oral solution, and injection?

Finished-goods supply for ganciclovir is typically held by:

• branded manufacturers for originator product (where applicable by market),
• generic manufacturers producing ANDA products in the US (and equivalents in EU member states),
• CDMOs that produce drug product under brand owner labels.

Dosage-form split

• Oral capsules and oral solution: focus on dose uniformity, content and dissolution.
• Injectable (IV): sterile manufacture, endotoxin, sterility assurance, and cold-chain logistics where specified.

How do supplier choices differ for oral vs IV ganciclovir?

• Oral forms: more emphasis on granulation, blend uniformity, and dissolution.
• Injectable: higher barrier manufacturing, including aseptic processing, container closure integrity testing, and sterile filtration validation.

How many ganciclovir manufacturers supply the US market and which are most active?

Ganciclovir supply in the US is served by multiple ANDA holders and their manufacturing networks. Supplier activity changes with:

• ANDA approvals and site transfers,
• patent and exclusivity timelines (affecting the number of viable entrants),
• drug product shortages and procurement shifts.

What supplier set is most relevant to procurement decisions?

For a buyer, the decision set is narrow:

• validated commercial manufacturing sites with consistent batch release history,
• suppliers with regulatory-ready documentation (CoA, stability, comparability),
• sites able to support the buyer’s forecast cadence without supply interruptions.

What is the biggest supply risk for ganciclovir and how do companies mitigate it?

Primary supply risks include:

• API intermediate availability and yield variability for nucleoside analog routes.
• Quality deviations around impurity profiles and polymorphic behavior.
• Limited sterile fill-finish capacity for injectable strengths during broader antiviral demand spikes.

Mitigation strategies used in market

• Dual sourcing API from at least two independent sites.
• Forward scheduling of long lead-time sterile components (bags, vials, stoppers) and fill-finish slots.
• Qualification of alternative packaging configurations where regulatory and stability allow.

What input suppliers exist for ganciclovir intermediates and nucleoside chemistry feedstocks?

Ganciclovir supply depends on upstream chemical feedstocks and intermediates used in guanine nucleoside analog synthesis. Buyers often treat these as part of the API supplier’s controlled supply chain rather than direct commodity procurement, but qualification and audit requirements are common.

Upstream categories buyers care about

• guanine base and protected intermediates,
• glycosylation reagents and protecting group chemistry materials,
• solvents and purification media with controlled impurity profiles,
• analytical reference standards for identity and impurity methods.

Which ganciclovir strengths and dosage forms face the highest procurement constraints?

Procurement constraints are typically more acute for:

• IV ganciclovir, due to sterile manufacturing bottlenecks,
• specific strengths that have fewer ANDA manufacturing sites or limited fill-finish throughput,
• lots that require tighter impurity specs tied to stability performance.

What is the most common contracting structure for ganciclovir supply?

Common contracting models in ganciclovir procurement include:

• supply agreements with minimum order quantities (MOQs) tied to campaign manufacturing,
• framework agreements with call-off schedules for API and finished product,
• quality agreements covering change control, notification windows, and deviation handling.

How does ganciclovir sourcing compare with valganciclovir and other antivirals?

Ganciclovir and valganciclovir share antiviral nucleoside analog market characteristics:

• Both face impurity and polymorph control requirements.
• Injectable supply bottlenecks are common for IV-originated antivirals.
• Buyers often use multi-product supplier portfolios at API level to stabilize demand.

Key difference is formulation complexity:

• valganciclovir is an L-valyl ester prodrug, which shifts upstream intermediate complexity and impurity controls.
• ganciclovir manufacturing focuses on the nucleoside core and its controlled impurities.

What licensing or regulatory status affects which ganciclovir suppliers can sell?

Supplier eligibility can be constrained by:

• ANDA exclusivity periods for first-filing generics,
• patent estate barriers for method-of-use or formulation claims in certain markets,
• site-specific manufacturing approvals and inspection outcomes.

Practical procurement impact

• Buyers often see fewer competitive bids during exclusivity windows or after manufacturing site sanctions.
• Supplier landscape expands when additional ANDA manufacturing sites are added or when quality events resolve.

Key Takeaways

• Ganciclovir supply is split between API manufacturers and finished-goods makers; injectable drug product has higher manufacturing and release barriers than oral forms.
• Procurement risk clusters around nucleoside intermediate availability, impurity control, and sterile fill-finish capacity for IV.
• Supplier qualification for ganciclovir is dominated by regulatory-ready documentation (DMF/ASMF linkage where used), consistent impurity profiles, and validated sterile manufacturing sites for injection.

FAQs

1. Which suppliers provide ganciclovir API with regulatory-ready DMF or ASMF documentation?
2. What manufacturing sites are most reliable for ganciclovir injectable sterile fill-finish?
3. How do buyers qualify alternative ganciclovir API suppliers to avoid impurity drift and stability failures?
4. Which ganciclovir dosage forms tend to experience shortages and why?
5. How does ganciclovir supplier quality history affect ANDA batch release and procurement continuity?

References

1. FDA. “ANDA Drug Products: Patent and Exclusivity Information.” U.S. Food and Drug Administration.
2. FDA. “Drug Shortages.” U.S. Food and Drug Administration.
3. FDA. “Drugs@FDA.” U.S. Food and Drug Administration.